JP2021531282A5 - - Google Patents

Info

Publication number
JP2021531282A5
JP2021531282A5 JP2021502772A JP2021502772A JP2021531282A5 JP 2021531282 A5 JP2021531282 A5 JP 2021531282A5 JP 2021502772 A JP2021502772 A JP 2021502772A JP 2021502772 A JP2021502772 A JP 2021502772A JP 2021531282 A5 JP2021531282 A5 JP 2021531282A5
Authority
JP
Japan
Prior art keywords
nucleic acid
otc
composition according
less
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021502772A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021531282A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/042069 external-priority patent/WO2020018583A1/en
Publication of JP2021531282A publication Critical patent/JP2021531282A/ja
Publication of JP2021531282A5 publication Critical patent/JP2021531282A5/ja
Pending legal-status Critical Current

Links

JP2021502772A 2018-07-16 2019-07-16 Otcコンストラクトおよびベクターの方法および組成物 Pending JP2021531282A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862698503P 2018-07-16 2018-07-16
US62/698,503 2018-07-16
US201962839766P 2019-04-28 2019-04-28
US62/839,766 2019-04-28
PCT/US2019/042069 WO2020018583A1 (en) 2018-07-16 2019-07-16 Methods and compositions of otc constructs and vectors

Publications (2)

Publication Number Publication Date
JP2021531282A JP2021531282A (ja) 2021-11-18
JP2021531282A5 true JP2021531282A5 (cg-RX-API-DMAC10.html) 2022-07-15

Family

ID=67544350

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021502772A Pending JP2021531282A (ja) 2018-07-16 2019-07-16 Otcコンストラクトおよびベクターの方法および組成物

Country Status (11)

Country Link
US (1) US20200038462A1 (cg-RX-API-DMAC10.html)
EP (1) EP3823980A1 (cg-RX-API-DMAC10.html)
JP (1) JP2021531282A (cg-RX-API-DMAC10.html)
KR (1) KR20210032438A (cg-RX-API-DMAC10.html)
CN (1) CN112771070A (cg-RX-API-DMAC10.html)
AU (1) AU2019308567A1 (cg-RX-API-DMAC10.html)
BR (1) BR112021000763A2 (cg-RX-API-DMAC10.html)
CA (1) CA3106639A1 (cg-RX-API-DMAC10.html)
IL (1) IL280149A (cg-RX-API-DMAC10.html)
MX (1) MX2021000637A (cg-RX-API-DMAC10.html)
WO (1) WO2020018583A1 (cg-RX-API-DMAC10.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107320734A (zh) 2011-04-29 2017-11-07 西莱克塔生物科技公司 从合成纳米载体中控制释放免疫抑制剂
CN105307641A (zh) 2013-05-03 2016-02-03 西莱克塔生物科技公司 用于降低不期望体液免疫应答的给药组合
EA201790551A1 (ru) 2014-09-07 2017-07-31 Селекта Байосайенсиз, Инк. Способы и композиции для ослабления иммунных ответов к пропускающему экзон вирусному трансферному вектору
EP4599848A3 (en) 2017-03-11 2025-12-03 Cartesian Therapeutics, Inc. Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
US12553041B2 (en) 2019-06-04 2026-02-17 Cartesian Therapeutics Inc. Formulations and doses of pegylated uricase
MX2023005224A (es) * 2020-11-04 2023-07-18 Selecta Biosciences Inc Composiciones para reducir las respuestas inmunes contra inmunoglobulina proteasas.
JP2024515626A (ja) 2021-04-16 2024-04-10 アスクレピオス バイオファーマシューティカル, インコーポレイテッド 血液脳関門を横断し低減された液性応答を惹起する合理的ポリプロイドaavビリオン
EP4328313A4 (en) * 2021-04-21 2025-06-25 Jichi Medical University Adeno-associated virus virion for treating ornithine transcarbamylase deficiency
US20230140196A1 (en) * 2021-10-12 2023-05-04 Selecta Biosciences, Inc. Viral vector dosing protocols
WO2025229995A1 (ja) * 2024-04-30 2025-11-06 学校法人自治医科大学 核酸導入用ベクター、核酸導入方法、ポリヌクレオチド、及びベクター
WO2025256978A1 (en) 2024-06-13 2025-12-18 Bayer Aktiengesellschaft Variants of igm and igg cleaving enzymes
WO2025256977A1 (en) 2024-06-13 2025-12-18 Bayer Aktiengesellschaft Novel igm and igg cleaving enzymes

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946929A (en) 1983-03-22 1990-08-07 Massachusetts Institute Of Technology Bioerodible articles useful as implants and prostheses having predictable degradation rates
US4638045A (en) 1985-02-19 1987-01-20 Massachusetts Institute Of Technology Non-peptide polyamino acid bioerodible polymers
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4806621A (en) 1986-01-21 1989-02-21 Massachusetts Institute Of Technology Biocompatible, bioerodible, hydrophobic, implantable polyimino carbonate article
US5736372A (en) 1986-11-20 1998-04-07 Massachusetts Institute Of Technology Biodegradable synthetic polymeric fibrous matrix containing chondrocyte for in vivo production of a cartilaginous structure
CA1340581C (en) 1986-11-20 1999-06-08 Joseph P. Vacanti Chimeric neomorphogenesis of organs by controlled cellular implantation using artificial matrices
US5759830A (en) 1986-11-20 1998-06-02 Massachusetts Institute Of Technology Three-dimensional fibrous scaffold containing attached cells for producing vascularized tissue in vivo
US5019379A (en) 1987-07-31 1991-05-28 Massachusetts Institute Of Technology Unsaturated polyanhydrides
US5010167A (en) 1989-03-31 1991-04-23 Massachusetts Institute Of Technology Poly(amide-and imide-co-anhydride) for biological application
US5399665A (en) 1992-11-05 1995-03-21 Massachusetts Institute Of Technology Biodegradable polymers for cell transplantation
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
US5512600A (en) 1993-01-15 1996-04-30 Massachusetts Institute Of Technology Preparation of bonded fiber structures for cell implantation
US5514378A (en) 1993-02-01 1996-05-07 Massachusetts Institute Of Technology Biocompatible polymer membranes and methods of preparation of three dimensional membrane structures
US5565215A (en) 1993-07-23 1996-10-15 Massachusettes Institute Of Technology Biodegradable injectable particles for imaging
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US6007845A (en) 1994-07-22 1999-12-28 Massachusetts Institute Of Technology Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
US5716404A (en) 1994-12-16 1998-02-10 Massachusetts Institute Of Technology Breast tissue engineering
US6123727A (en) 1995-05-01 2000-09-26 Massachusetts Institute Of Technology Tissue engineered tendons and ligaments
US6001650A (en) 1995-08-03 1999-12-14 Avigen, Inc. High-efficiency wild-type-free AAV helper functions
US6095148A (en) 1995-11-03 2000-08-01 Children's Medical Center Corporation Neuronal stimulation using electrically conducting polymers
US5902599A (en) 1996-02-20 1999-05-11 Massachusetts Institute Of Technology Biodegradable polymer networks for use in orthopedic and dental applications
WO1998002441A2 (en) 1996-07-12 1998-01-22 Ariad Pharmaceuticals, Inc. Non immunosuppressive antifungal rapalogs
US5837752A (en) 1997-07-17 1998-11-17 Massachusetts Institute Of Technology Semi-interpenetrating polymer networks
US6506577B1 (en) 1998-03-19 2003-01-14 The Regents Of The University Of California Synthesis and crosslinking of catechol containing copolypeptides
US6686446B2 (en) 1998-03-19 2004-02-03 The Regents Of The University Of California Methods and compositions for controlled polypeptide synthesis
US6632922B1 (en) 1998-03-19 2003-10-14 The Regents Of The University Of California Methods and compositions for controlled polypeptide synthesis
US6436392B1 (en) 1998-05-20 2002-08-20 University Of Iowa Research Foundation Adeno-associated virus vectors
US6759237B1 (en) 1998-11-05 2004-07-06 The Trustees Of The University Of Pennsylvania Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
WO2000074688A1 (en) * 1999-06-08 2000-12-14 The Children's Hospital Of Philadelphia Methods for preventing formation of inhibitory antibodies in the setting of gene therapy
MXPA02008361A (es) 2000-02-28 2004-05-17 Genesegues Inc Sistema y metodo de encapsulacion de nanocapsulas.
EP1278542A2 (en) 2000-05-05 2003-01-29 Cytos Biotechnology AG Molecular antigen arrays and vaccines
US7465583B2 (en) 2000-06-01 2008-12-16 The University Of North Carolina At Chapel Hill Duplexed parvovirus vectors
CA2319928A1 (en) 2000-09-18 2002-03-18 Vasogen Ireland Limited Apoptosis-mimicking synthetic entities and use thereof in medical treatments
GB0025414D0 (en) 2000-10-16 2000-11-29 Consejo Superior Investigacion Nanoparticles
WO2003020797A1 (en) 2001-08-30 2003-03-13 The Regents Of The University Of California Transition metal initiators for controlled poly (beta-peptide) synthesis from beta-lactam monomers
DK2359869T3 (en) 2001-12-17 2019-04-15 Univ Pennsylvania Sequences of adeno-associated virus (AAV) serotype 8, vectors containing these, and uses thereof
US7510872B2 (en) 2003-02-26 2009-03-31 Nationwide Children's Hospital Recombinant adeno-associated virus production
CN101675993A (zh) 2003-03-26 2010-03-24 赛托斯生物技术公司 Melan-a肽类似物-病毒样颗粒偶联物
US7186699B2 (en) 2003-06-03 2007-03-06 Cell Genesys, Inc. Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
EP1486567A1 (en) 2003-06-11 2004-12-15 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Improved adeno-associated virus (AAV) vector for gene therapy
WO2005101466A2 (en) 2003-12-19 2005-10-27 The University Of North Carolina At Chapel Hill Methods for fabricating isolated micro- and nano- structures using soft or imprint lithography
WO2006080951A2 (en) 2004-07-01 2006-08-03 Yale University Targeted and high density drug loaded polymeric materials
US20090226525A1 (en) 2007-04-09 2009-09-10 Chimeros Inc. Self-assembling nanoparticle drug delivery system
JP2010523656A (ja) 2007-04-12 2010-07-15 エモリー・ユニバーシティ ミセルおよび粒子を用いた、活性物質の送達のための新規の戦略
MX2010003642A (es) 2007-10-12 2010-08-09 Massachusetts Inst Technology Nanotecnologia de vacuna.
WO2009106999A2 (en) 2008-02-28 2009-09-03 Deutsches Krebsforschungszentrum, Stiftung Des Öffentlichen Rechts Hollow nanoparticles and uses thereof
CN101676291B (zh) 2008-09-18 2012-05-09 上海海和药物研究开发有限公司 一类雷帕霉素碳酸酯类似物、其药物组合物及其制备方法和用途
WO2010047839A1 (en) 2008-10-25 2010-04-29 Aura Biosciences Modified plant virus particles and uses therefor
US8679837B2 (en) 2009-04-02 2014-03-25 University Of Florida Research Foundation, Inc. Inducible system for highly efficient production of recombinant Adeno-associated virus (rAAV) vectors
US8927514B2 (en) 2010-04-30 2015-01-06 City Of Hope Recombinant adeno-associated vectors for targeted treatment
ES2685611T3 (es) 2011-02-14 2018-10-10 The Children's Hospital Of Philadelphia Vector VAA8 mejorado con una actividad funcional aumentada y métodos de utilización del mismo
US20140155469A1 (en) 2011-04-19 2014-06-05 The Research Foundation Of State University Of New York Adeno-associated-virus rep sequences, vectors and viruses
JP6342886B2 (ja) 2012-04-18 2018-06-13 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアThe Children’S Hospital Of Philadelphia Aavカプシドバリアントを使用した高効率な遺伝子導入のための組成物及び方法
BR112016020688B1 (pt) * 2014-03-09 2024-01-30 The Trustees Of The University Of Pennsylvania Vetores virais recombinantes, vírus adenoassociado recombinante, composição farmacêutica, bem como uso dos mesmos
US10181193B2 (en) * 2014-03-10 2019-01-15 Microsoft Technology Licensing, Llc Latency reduction in camera-projection systems
EA201790551A1 (ru) * 2014-09-07 2017-07-31 Селекта Байосайенсиз, Инк. Способы и композиции для ослабления иммунных ответов к пропускающему экзон вирусному трансферному вектору
CN107002096A (zh) * 2014-10-06 2017-08-01 阿罗根有限公司 基于aav的基因疗法
US11104887B2 (en) * 2017-01-03 2021-08-31 Ethris Gmbh Ornithine transcarbamylase coding polyribonucleotides and formulations thereof

Similar Documents

Publication Publication Date Title
Chen et al. Tumor-associated-macrophage-membrane-coated nanoparticles for improved photodynamic immunotherapy
Sun et al. The drug release of PLGA-based nanoparticles and their application in treatment of gastrointestinal cancers
Karabasz et al. Biomedical applications of multifunctional polymeric nanocarriers: A review of current literature
Lara-Velazquez et al. Chitosan-based non-viral gene and drug delivery systems for brain cancer
Stuckey et al. TRAIL on trial: preclinical advances in cancer therapy
JP2021530571A5 (cg-RX-API-DMAC10.html)
Meyer et al. A scalable and robust cationic lipid/polymer hybrid nanoparticle platform for mRNA delivery
Zhou et al. Stimuli-responsive nanomedicines for overcoming cancer multidrug resistance
Mu et al. Nanoparticles for imaging and treatment of metastatic breast cancer
Xie et al. Immunoengineering with biomaterials for enhanced cancer immunotherapy
Xu et al. Development of targeted therapies in treatment of glioblastoma
CN103687590A (zh) 用于靶向给药的多孔纳米颗粒支撑脂双层(原始细胞)及其使用方法
WO2019097250A1 (en) Particles for the treatment of cancer in combination with radiotherapy
Jiang et al. Development of intratumoral drug delivery based strategies for antitumor therapy
JP2020505403A5 (cg-RX-API-DMAC10.html)
CA2899155A1 (en) Biodegradable and clinically-compatible nanoparticles as drug delivery carriers
Liu et al. Multifunctional nano-in-micro delivery systems for targeted therapy in fundus neovascularization diseases
Sawant et al. Cancer research and therapy: Where are we today
Greish et al. Silk‐elastinlike protein polymers improve the efficacy of adenovirus thymidine kinase enzyme prodrug therapy of head and neck tumors
Liu et al. Move to Nano‐Arthrology: Targeted stimuli‐responsive nanomedicines combat Adaptive Treatment Tolerance (ATT) of rheumatoid arthritis
JP2004501870A (ja) ガン患者における化学療法の副作用を軽減させる方法
Okuda et al. Targeted therapy for acute autoimmune myocarditis with nano-sized liposomal FK506 in rats
Shi et al. Advances in nanotherapy for targeting senescent cells
Nasr et al. Realizing time-staggered expression of nucleic acid-encoded proteins by co-delivery of messenger RNA and plasmid DNA on a single nanocarrier
Du et al. Efficient suppression of liver metastasis cancers by paclitaxel loaded nanoparticles in PDLLA-PEG-PDLLA thermosensitive hydrogel composites